


CLAIM AMENDMENTS

1. (currently amended): A compound of formula I



I

or a pharmaceutically acceptable salts or diastereomers salt or diastereomer thereof, wherein:

A is NR^1 , where R^1 is H, or C_{1-4} alkyl;

B is phenyl optionally substituted with 0-4 substituents independently selected from halogen, C_{1-4} alkyl, CF_3 , CN, aryl, OH, OCF_3 , OC_{1-4} alkyl, OC_{2-5} alkyl NR^2R^3 , Oaryl, CO_2R^2 , CONR^2R^3 , NR^2R^3 , $\text{NR}^4\text{C}_{1-4}$ alkyl NR^2R^3 , NR^2COR^3 , $\text{OC(O)NR}^2\text{R}^3$, $\text{NR}^4\text{CONR}^2\text{R}^3$, and $\text{NR}^2\text{SO}_2\text{R}^3$;

wherein R^2 , R^3 are each independently H, C_{1-4} alkyl, aryl, C_{1-4} alkyl aryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing one of O, S, or NR^5 ;

wherein R^4 is H or C_{1-4} alkyl; and

wherein R^5 is H or C_{1-4} alkyl;

Q is a bond when W is absent, and is C_{1-4} alkyl when W is present;

W is selected from H, C_{1-4} alkyl, C_{2-6} alkenyl; where C_{1-4} alkyl or C_{2-6} alkenyl may be optionally substituted with C_{1-4} alkyl, OH, OC_{1-4} alkyl, $\text{NR}^6\text{C(O)R}^7$, CONR^6R^7 , OR^6 , or NR^6R^7 ;

wherein R^6 , and R^7 are each independently H, C_{1-4} alkyl, C_{1-4} alkyl cycloalkyl, aryl, or may be joined to form an optionally substituted 3-8 membered ring, and

Y is [[H or]] phenyl, optionally substituted with 0-3 substituents independently selected from halogen, C_{1-4} alkyl, CF_3 , aryl, OH, OCF_3 , CN, C_{2-4} alkynyl, OC_{1-4} alkyl, OC_{2-5} alkyl NR^9R^{10} , Oaryl, $[\text{CO}_2\text{R}^9]$ $\text{CONR}^9\text{R}^{10}$, NR^9R^{10} , C_{1-4} alkyl NR^9R^{10} , $\text{NR}^{11}\text{C}_{1-4}$ alkyl NR^9R^{10} , $\text{NR}^9\text{COR}^{10}$, $\text{NR}^{11}\text{CONR}^9\text{R}^{10}$, and $\text{NR}^9\text{SO}_2\text{R}^{10}$;

wherein R^9 and R^{10} is each independently H, C_{1-4} alkyl, aryl, C_{1-4} alkyl aryl, or may be joined to form an optionally substituted 3-8 membered ring;

wherein R^{11} is H or C_{1-4} alkyl[[:]]

~~with the proviso that when Y is phenyl substituted at the ortho position with CO_2R^9 , CN or NH_2 , W is absent and Q is a bond, and B has one or zero substituents, then R^+ is C_{1-4} alkyl.~~

2. (currently amended): A compound according to claim 1 or a pharmaceutically acceptable salts or diastereomers salt or diastereomer thereof, wherein:

W is selected from H, C_{1-4} alkyl, and C_{2-6} alkenyl; wherein C_{1-4} alkyl or C_{2-6} alkenyl may be optionally substituted with C_{1-4} alkyl, OH, OC_{1-4} alkyl, or NR^6R^7 ;


wherein R^6 , and R^7 are each independently H, C_{1-4} alkyl, C_{1-4} alkyl cycloalkyl, aryl, or may be joined to form an optionally substituted 3-8 membered ring;

Y is [[H or]] phenyl optionally substituted with 0-3 substituents independently selected from halogen, C_{1-4} alkyl, CF_3 , aryl, OH, OCF_3 , OC_{1-4} alkyl, OC_{2-5} alkyl NR^9R^{10} , Oaryl, $[[CO_2R^9,]]$ $CONR^9R^{10}$, NR^9R^{10} , C_{1-4} alkyl NR^9R^{10} , $NR^{11}C_{1-4}$ alkyl NR^9R^{10} , NR^9COR^{10} , $NR^{11}CONR^9R^{10}$, and $NR^9SO_2R^{10}$;


wherein R^9 , and R^{10} are each independently H, C_{1-4} alkyl, aryl, C_{1-4} alkyl aryl, or may be joined to form an optionally substituted 3-8 membered ring; and

wherein R^{11} is H or C_{1-4} alkyl.


3. (currently amended): A compound ~~according to claim 1 wherein the compound is~~ selected from the group consisting of:




C22H22N2O4




C23H23ClN2O4




C20H18N2O2




C22H20ClFN2O4




C19H15FN2O2




C22H20ClFN2O4




C19H16N2O2




C22H21ClN2O4




C20H19N3O2




C23H24N2O4




C21H19FN2O2




C19H18N2O3




C22H22N2O2




C21H19FN2O2




C21H20N2O2




C21H20N2O2




C21H20N2O2




C22H22N2O3




C21H20N2O2




C20H17FN2O2




C20H17FN2O2




C20H18N2O2




C19H16N2O2




C21H20N2O3




C22H22N2O4




C20H17FN2O3



C20H17FN2O3



C₂₁H₂₀N₂O₃



C₂₀H₁₈N₂O₃

[[or]] and a pharmaceutically acceptable salts or diastereomers salt or diastereomer thereof.

4. (previously presented): A pharmaceutical composition comprising a carrier and at least one compound of claim 1.

5-6. (canceled)

7. (previously presented): A pharmaceutical composition comprising a carrier and at least one compound of claim 2.

8. (previously presented): A pharmaceutical composition comprising a carrier and at least one compound of claim 3.